Related Experiment Video
Updated: May 11, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor
Anna Jamnitski1, Johannes H Levels, Inge A van den Oever
1Jan van Breemen Research Institute, Amsterdam, The Netherlands.
Objective:
We investigated changes in high-density lipoprotein (HDL) profiling in patients with rheumatoid arthritis who started treatment by taking tumor necrosis factor (TNF) inhibitors. The patients were stratified for European League Against Rheumatism (EULAR) response.
Methods:
A group of 100 patients naive for TNF inhibitors at baseline were randomly selected from 204 adalimumab-treated and 203 etanercept-treated patients on the basis of their EULAR response. HDL profiling was measured using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Results:
In EULAR good responders, mass charged markers representing serum amyloid A (SAA-1 and -2) decreased significantly after 4 months' therapy. There were no significant differences in HDL profiling in EULAR nonresponders.
Conclusion:
Effective suppression of inflammation with TNF inhibitors results in favorable changes in HDL composition.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Therapeutic Drug Monitoring: Affecting Factors
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies